Skip to content
zPREDICTA logo

zPREDICTA

zPREDICTA is a YC Summer 2015 (S15) company. Based in San Jose, CA, USA. Team of 2.

About zPREDICTA

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

zPREDICTA builds organ-specific 3D cell culture models that reconstruct human tumor tissue, including the surrounding cellular and extracellular microenvironment, for preclinical drug testing. Pharmaceutical and academic researchers use the platform to screen anticancer compounds, study drug resistance mechanisms, and assess off-target toxicity. The models replace conventional 2D cell culture and animal models with a system whose readouts correlate directly with clinical drug response, letting researchers eliminate failing compounds earlier.

Go-to-market

Researchers in oncology drug discovery, including those working on immuno-oncology agents and failed drug candidate rescue, are the primary buyers. The platform is sold as a research service or model system compatible with multiple drug classes, cell types, and assay readouts.

From the Y Combinator listing

How zPREDICTA describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Patient-derived 3D tissue reconstruction models for preclinical…

zPREDICTA is developing organ-specific, physiologically-relevant 3D cell culture models providing a 1-to-1 reconstruction of human tissues. This is the only available 3D culture approach that comprehensively accounts for the major components of the cellular and extracellular tissue microenvironment preserving the critical interactions between a tumor and its surroundings. Clinical study data demonstrate the high correlation between drug efficacy measured in our platform and the clinical response. The ability of the zPREDICTA platform to reliably predict clinical outcomes offers superior compound attrition management, empowering researchers to exclude ineffective compounds while selecting agents with a high probability of success in the clinic. Our approach is compatible with any drug class, multiple tissue/cell types and a wide variety of readouts. Our customers are using these models for efficacy screening of anticancer compounds, including immuno-oncology agents, evaluation of mechanisms of drug resistance, the rescue of failed drug candidates, assessment of off-target toxicity, and a multitude other applications.

Facts

Industry
Healthcare / Healthcare -> Drug Discovery and Delivery
Location
San Jose, CA, USA
Team size
2
Status
Acquired
Stage
Early

Founders (1)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works